High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery

Antiviral Research

Volumn 80, Issue 2, 2008, Pages 107-113

  Ge, Feng ^a   Xiong, Sheng ^a   Lin, Fu Sen ^b   Zhang, Zhi Ping ^c   Zhang, Xian En ^c  

^a JINAN UNIVERSITY   (China)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

High throughput screen (HTS); SARS CoV replicon

Indexed keywords

2 AMINO 6 [(4 CHLOROPHENYL)THIO] 4 (2 THIENYL)PYRIDINE 3,5 DICARBONITRILE; 3 (4 CHLOROBENZENESULFONYL)PROPIONAMIDE; 3 QUINOLINECARBOXYLIC ACID 1,4,5,6,7,8 HEXAHYDRO 2 METHYL 4 (2 NITROPHENYL) 5 OXO 2 PHENYLETHYL ESTER; 4 BENZYLAMINO 6 ETHOXYQUINOLINE 3 CARBOXYLIC ACID ETHYL ESTER; ANTIVIRUS AGENT; BENZAMIDE DERIVATIVE; C 01225; C 03455; C 11472; C 12344; C 26505; C 38477; C 47655; CARBOXYLIC ACID DERIVATIVE; CYANIDE; DODECAHYDRO 17 (2 HYDROXY 6 METHYLHEPT 5 EN 2 YL) 4,4,8,10 TETRAMETHYL 2H CYCLOPENTA[A]PHENANTHREN 3(4H,9H,14H) ONE; GREEN FLUORESCENT PROTEIN; N ACETYL S NITROSOPENICILLAMINE; N' (2 AMINOACETYL) 2 (BENZAMIDO) 3 (4 HYDROXY 3 METHOXYPHENYL)ACRYLOHYDRAZIDE; PHENANTHRENE DERIVATIVE; PROPIONAMIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG IDENTIFICATION; HIGH THROUGHPUT SCREENING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPLICON; SARS CORONAVIRUS; VIRUS CULTURE; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; DRUG EVALUATION, PRECLINICAL; GREEN FLUORESCENT PROTEINS; HUMANS; REPLICON; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SMALL MOLECULE LIBRARIES; VERO CELLS; VIRUS REPLICATION;

CORONAVIRUS; SARS CORONAVIRUS;

EID: 53449095669     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.05.005     Document Type: Article

References (22)

1. Drosten C., Günther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguière A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Müller S., Rickerts V., Stürmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., and Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1976
2. Ge F., Luo Y.H., Liew P.X., and Hung E. Derivation of a novel SARS-coronavirus replicon cell line and its application for anti-SARS drug screening. Virology 360 (2007) 150-158
3. Gu B.H., Ouzunov S., Wang L.G., Mason P., Bourne N., Cuconati A., and Block T.M. Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen. Antiviral Res. 70 (2006) 39-50
4. Hertzig T., Scandella E., Schelle B., Ziebuhr J., Siddell S.G., Ludewig B., and Thiel V. Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J. Gen. Virol. 85 (2004) 1717-1725
5. Hofmann H., and Pöhlmann S. Cellular entry of the SARS coronavirus. Trends Microbiol. 12 (2004) 466-472
6. Ivens T., Van den Eynde C., Van Acker K., Nijs E., Dams G., Bettens E., Ohagen A., Pauwels R., and Hertogs K. Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus. J. Virol. Methods 129 (2005) 56-63
7. Kao R.Y., To A.P., Ng L.W., Tsui W.H., Lee T.S., Tsoi H.W., and Yuen K.Y. Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. FEBS Lett. 576 (2004) 325-330
8. Kao R.Y., Tsui W.H., Lee T.S., Tanner J.A., Watt R.M., Huang J.D., Hu L., Chen G., Chen Z., Zhang L., He T., Chan K.H., Tse H., To A.P., Ng L.W., Wong B.C., Tsoi H.W., Yang D., Ho D.D., and Yuen K.Y. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem. Biol. 11 (2004) 1293-1299
9. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc L.W., Bellini W.J., and Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
10. Lai L.H., Han X.F., Chen H., Wei P., Huang C.K., Liu S.Y., Fan K.Q., Zhou L., Liu Z.M., Pei J.F., and Liu Y. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase. Curr. Pharm. Des. 12 (2006) 4555-4564
11. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., and Roper R.L. The genome sequence of the SARS-associated coronavirus. Science 300 (2003) 1399-1404
12. Peiris J.S.M., Yuen K.Y., Osterhaus A.D.M., and Stöhr K. The severe acute respiratory syndrome. N. Engl. J. Med. 349 (2003) 2431-2441
13. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., and Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75 (2001) 1252-1264
14. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Günther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., and Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
15. Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E., and Ziebuhr J. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84 (2003) 2305-2315
16. Thiel V., Karl N., Schelle B., Disterer P., Klagge I., and Siddell S.G. Multigene RNA vector based on coronavirus transcription. J. Virol. 77 (2003) 9790-9798
17. Wu C.Y., Jan J.T., Ma S.H., Kuo C.J., Juan H.F., Cheng Y.S., Hsu H.H., Huang H.C., Wu D., Brik A., Liang F.S., Liu R.S., Fang J.M., Chen S.T., Liang P.H., and Wong C.H. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10012-10017
18. Yang H.T., Bartlam M., and Rao Z.H. Drug design targeting the main protease, the Achilles' heel of coronaviruses. Curr. Pharm. Des. 12 (2006) 4573-4590
19. Yount B., Curtis K.M., and Baric R.S. Strategy for systematic assembly of large RNA and DNA genomes: transmissible gastroenteritis virus model. J. Virol. 74 (2000) 10600-10611
20. Yount B., Curtis K.M., Fritz E.A., Hensley L.E., Jahrling P.B., Prentice E., Denison M.R., Geisbert T.W., and Baric R.S. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 12995-13000
21. Zhong N.S., Zheng B.J., Li Y.M., Xie Z.H., Chan K.H., Li P.H., Tan S.Y., Chang Q., Xie J.P., Liu X.Q., Xu J., Li D.X., Yuen K.Y., Peiris J.S., and Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February. Lancet 362 (2003) 1353-1358
22. Ziebuhr J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr. Opin. Microbiol. 7 (2004) 412-419